Literature DB >> 32040814

Prognostic Potential of Lymphocyte-C-Reactive Protein Ratio in Patients with Rectal Cancer Receiving Preoperative Chemoradiotherapy.

Yoshinaga Okugawa1, Yuji Toiyama2, Hiroyuki Fujikawa2, Shozo Ide2, Akira Yamamoto2, Yusuke Omura2, Chengzeng Yin2, Kurando Kusunoki2, Yukina Kusunoki2, Hiromi Yasuda2, Takeshi Yokoe2, Junichiro Hiro2, Masaki Ohi2, Masato Kusunoki2.   

Abstract

PURPOSE: The systemic inflammatory response is attracting increasing attention as a predictive biomarker for oncological outcome in patients with colorectal cancer. This study is aimed at verifying if the lymphocyte-C-reactive protein (CRP) ratio (LCR) could be used as a predictor of oncological outcome in patients with rectal cancer (RC) receiving preoperative chemoradiotherapy (CRT).
METHODS: We analyzed data for 86 patients with RC who received preoperative CRT followed by total mesorectal excision at our institution. A ratio of 6000 was used as the cut-off value for LCR for further analysis.
RESULTS: The post-CRT LCR was significantly lower than the pre-CRT LCR in patients with RC. Although post-CRT LCR status was not significantly correlated with overall survival (OS), low pre-CRT LCR was significantly associated with shorter recurrence-free survival (RFS: p = 0.02) and OS (p = 0.017) in this population and was an independent prognostic factor for both RFS and OS (hazard ratio (HR) 3.19, 95% confidence interval (CI) 1.33-7.66, p = 0.009; HR 2.83, 95%CI 1.14-7.01, p = 0.025, respectively). Furthermore, low pre-CRT LCR was a stronger indicator of early recurrence (p = 0.001) and poor prognosis (p = 0.025) in RC patients without pathological lymph node metastasis compared with patients with pathological lymph node metastasis, and prognostic potential of pre-CRT LCR was clearly revealed especially RC patients receiving long-course CRT.
CONCLUSIONS: Assessment of pretreatment LCR status might aid decision-making regarding postoperative treatment strategies in patients with RC receiving CRT followed by potentially curative resection.

Entities:  

Keywords:  Chemoradiotherapy; Lymphocyte–C-reactive protein ratio; Rectal cancer

Mesh:

Substances:

Year:  2020        PMID: 32040814     DOI: 10.1007/s11605-019-04495-4

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  26 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

3.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

4.  Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery.

Authors:  Yuji Toiyama; Yasuhiro Inoue; Mikio Kawamura; Aya Kawamoto; Yoshinaga Okugawa; Jyunichiro Hiro; Susumu Saigusa; Koji Tanaka; Yasuhiko Mohri; Masato Kusunoki
Journal:  Int Surg       Date:  2015-02

Review 5.  Total neoadjuvant therapy for rectal cancer: An emerging option.

Authors:  Ethan B Ludmir; Manisha Palta; Christopher G Willett; Brian G Czito
Journal:  Cancer       Date:  2017-03-10       Impact factor: 6.860

6.  Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.

Authors:  R Yoshikawa; M Kusunoki; H Yanagi; M Noda; J I Furuyama; T Yamamura; T Hashimoto-Tamaoki
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

7.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

8.  The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Authors:  Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

Review 9.  Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer.

Authors:  S Gollins; D Sebag-Montefiore
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-11-29       Impact factor: 4.126

10.  Clinical significance of enlarged lateral pelvic lymph nodes before and after preoperative chemoradiotherapy for rectal cancer.

Authors:  Yasuhiro Inoue; Susumu Saigusa; Junichiro Hiro; Yuji Toiyama; Toshimitsu Araki; Koji Tanaka; Yaushiko Mohri; Masato Kusunoki
Journal:  Mol Clin Oncol       Date:  2016-04-08
View more
  11 in total

1.  The Association of the Lymphocyte-to-C-Reactive-Protein Ratio With Gastric Cancer Patients Who Receive Curative Treatment.

Authors:  Toru Aoyama; Masato Nakazano; Shinsuke Nagasawa; Kentaro Hara; Keisuke Komori; Hiroshi Tamagawa; Yukio Maezawa; Kenki Segami; Kazuki Kano; Takashi Ogata; Norio Yukawa; Yasushi Rino; Takashi Oshima
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

2.  Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study.

Authors:  Li Wang; Yu-Ling Zhang; Chang Jiang; Fang-Fang Duan; Zhong-Yu Yuan; Jia-Jia Huang; Xi-Wen Bi
Journal:  J Inflamm Res       Date:  2022-07-13

3.  Prognostic Role of Lymphocyte-C-Reactive Protein Ratio in Colorectal Cancer: A Systematic Review and Meta Analysis.

Authors:  Xinglong He; Ade Su; Yongcheng Xu; Diaolong Ma; Guoyuan Yang; Yiyun Peng; Jin Guo; Ming Hu; Yuntao Ma
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

4.  Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer.

Authors:  He-Yang Zhang; Hai-Lun Xie; Guo-Tian Ruan; Qi Zhang; Yi-Zhong Ge; Xiao-Yue Liu; Meng Tang; Meng-Meng Song; Shi-Qi Lin; Ming Yang; Xiao-Wei Zhang; Hong-Xia Xu; Chun-Hua Song; Han-Ping Shi
Journal:  BMC Cancer       Date:  2022-10-20       Impact factor: 4.638

5.  The role of hemogram parameters and C-reactive protein in predicting mortality in COVID-19 infection.

Authors:  Ethem Acar; Ahmet Demir; Birdal Yıldırım; Mehmet Gökhan Kaya; Kemal Gökçek
Journal:  Int J Clin Pract       Date:  2021-04-30       Impact factor: 3.149

6.  Prognostic Significance of Preoperative Lymphocyte-to-C-Reactive Protein Ratio in Patients with Non-Metastatic Colorectal Cancer.

Authors:  Wenting Ou; Caijin Zhou; Xiaoqing Zhu; Lin Lin; Qingwen Xu
Journal:  Onco Targets Ther       Date:  2021-01-12       Impact factor: 4.147

7.  C-Reactive Protein as Predictive Biomarker for Response to Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer: A Retrospective Study.

Authors:  Fátima Aires; Darlene Rodrigues; María Piñeiro Lamas; Maria Teresa Herdeiro; Adolfo Figueiras; Maria José Oliveira; Margarida Marques; Ana Teresa Pinto
Journal:  Cancers (Basel)       Date:  2022-01-19       Impact factor: 6.639

8.  Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer.

Authors:  Masaaki Nishi; Mistuo Shimada; Takuya Tokunaga; Jun Higashijima; Kozo Yoshikawa; Hideya Kashihara; Chie Takasu; Daichi Ishikawa; Yuma Wada; Shohei Eto; Toshiaki Yoshimoto
Journal:  World J Surg Oncol       Date:  2021-07-06       Impact factor: 2.754

9.  Clinical significance of C-Reactive Protein to Lymphocyte Count Ratio as a prognostic factor for Survival in Non-small Cell Lung Cancer Patients undergoing Curative Surgical Resection.

Authors:  Jae-Joon Hwang; Joon Young Hur; Wankyu Eo; Soomin An; Dae Hyun Kim; Sookyung Lee
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

Review 10.  Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients.

Authors:  Aylin Alkan; Tobias Hofving; Eva Angenete; Ulf Yrlid
Journal:  Biomark Res       Date:  2021-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.